-
1
-
-
84958800609
-
-
CDC. Deaths: Final data for 2013. 2014; Available from:. Accessed 30 Oct 2015
-
CDC. Deaths: Final data for 2013. 2014; Available from: http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Accessed 30 Oct 2015.
-
-
-
-
2
-
-
0033537343
-
Lifetime risk of developing coronary heart disease
-
PID: 10023892
-
Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92.
-
(1999)
Lancet
, vol.353
, pp. 89-92
-
-
Lloyd-Jones, D.M.1
Larson, M.G.2
Beiser, A.3
Levy, D.4
-
3
-
-
84920703518
-
Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990 – 2013 : a systematic analysis for the Global Burden of Disease Study 2013
-
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990 – 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;385(9963):117–71.
-
(2014)
Lancet
, vol.385
, Issue.9963
, pp. 117-171
-
-
GBD 2013 Mortality and Causes of Death Collaborators1
-
4
-
-
0035960630
-
Global burden of cardiovascular diseases
-
PID: 11723030
-
Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases. Circulation. 2001;104(C):2746–53.
-
(2001)
Circulation
, vol.104
, Issue.C
, pp. 2746-2753
-
-
Yusuf, S.1
Reddy, S.2
Ôunpuu, S.3
Anand, S.4
-
6
-
-
84897970506
-
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines
-
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 SUPPL 1):1–49.
-
(2014)
Circulation
, vol.129
, pp. 1-49
-
-
Stone, N.J.1
Robinson, J.G.2
Lichtenstein, A.H.3
Bairey Merz, C.N.4
Blum, C.B.5
Eckel, R.H.6
-
7
-
-
80052056208
-
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
-
PID: 21678374
-
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;6:CD008143.
-
(2011)
Cochrane Database Syst Rev
, vol.6
, pp. CD008143
-
-
Hemmingsen, B.1
Lund, S.S.2
Gluud, C.3
Vaag, A.4
Almdal, T.5
Hemmingsen, C.6
-
8
-
-
84941243068
-
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
-
PID: 26063450
-
Ferrannini E, Defronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288–96.
-
(2015)
Eur Heart J
, vol.36
, pp. 2288-2296
-
-
Ferrannini, E.1
Defronzo, R.A.2
-
9
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
UK Prospective Diabetes Study (UKPDS) Group1
-
10
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
PID: 26378978, Recent large-scale RCT in which empagliflozin, an inhibitor of sodium-glucose cotransporter 2 approved for type 2 diabetes mellitus, was associated with a lower rate of a composite outcome consisting of death from cardiovascular causes, nonfatal MI and nonfatal stroke, as well as a lower rate of all-cause mortality. These results are notable given the shortage of convincing evidence that antiglycemic therapy significantly improves macrovascular outcomes
-
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. Recent large-scale RCT in which empagliflozin, an inhibitor of sodium-glucose cotransporter 2 approved for type 2 diabetes mellitus, was associated with a lower rate of a composite outcome consisting of death from cardiovascular causes, nonfatal MI and nonfatal stroke, as well as a lower rate of all-cause mortality. These results are notable given the shortage of convincing evidence that antiglycemic therapy significantly improves macrovascular outcomes.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
-
11
-
-
44949089679
-
-
Shyangdan D, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus (review). Cochrane Database Syst Rev. 2011;10:CD006423.
-
Shyangdan D, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus (review). Cochrane Database Syst Rev. 2011;10:CD006423.
-
-
-
-
12
-
-
84923834407
-
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes
-
PID: 25565404
-
Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015;49(3):351–9.
-
(2015)
Ann Pharmacother
, vol.49
, Issue.3
, pp. 351-359
-
-
Thompson, A.M.1
Trujillo, J.M.2
-
13
-
-
84957448745
-
A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
-
Nauck MA, Petrie JR, Sesti G, Mannucci E, Courr J. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2015.
-
(2015)
Diabetes Care
-
-
Nauck, M.A.1
Petrie, J.R.2
Sesti, G.3
Mannucci, E.4
Courr, J.5
-
14
-
-
84929947880
-
GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond
-
PID: 25959380
-
Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity. 2015;23(6):1119–29.
-
(2015)
Obesity
, vol.23
, Issue.6
, pp. 1119-1129
-
-
Ryan, D.1
Acosta, A.2
-
15
-
-
84940775618
-
Multiple factors related to the secretion of glucagon-like peptide-1
-
PID: 26366173
-
Wang X, Liu H, Chen J, Li Y, Qu S. Multiple factors related to the secretion of glucagon-like peptide-1. Int J Endocrinol. 2015;2015:651757.
-
(2015)
Int J Endocrinol
, vol.2015
, pp. 651757
-
-
Wang, X.1
Liu, H.2
Chen, J.3
Li, Y.4
Qu, S.5
-
16
-
-
84937525129
-
Effects of exogenous glucagon-like peptide-1 on blood pressur, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes
-
PID: 26048234
-
Trahair LG, Horowitz M, Stevens JE, Feinle-Bisset C, Standfield S, Piscitelli D, et al. Effects of exogenous glucagon-like peptide-1 on blood pressur, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia. 2015;58:1769–78.
-
(2015)
Diabetologia
, vol.58
, pp. 1769-1778
-
-
Trahair, L.G.1
Horowitz, M.2
Stevens, J.E.3
Feinle-Bisset, C.4
Standfield, S.5
Piscitelli, D.6
-
17
-
-
43249089631
-
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways
-
PID: 18427132
-
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and independent pathways. Circulation. 2008;117:2340–50.
-
(2008)
Circulation
, vol.117
, pp. 2340-2350
-
-
Ban, K.1
Noyan-Ashraf, M.H.2
Hoefer, J.3
Bolz, S.4
Drucker, D.J.5
Husain, M.6
-
18
-
-
84939565602
-
Incretin-based therapies for obesity treatment
-
PID: 26072135
-
De Mello AH, Prá M, Cardoso LC, de Bona SR, Rezin GT. Incretin-based therapies for obesity treatment. Metabolism. 2015;64(9):967–81.
-
(2015)
Metabolism
, vol.64
, Issue.9
, pp. 967-981
-
-
De Mello, A.H.1
Prá, M.2
Cardoso, L.C.3
de Bona, S.R.4
Rezin, G.T.5
-
19
-
-
84964695799
-
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists
-
PID: 25338737
-
Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014;13:142.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 142
-
-
Saraiva, F.K.1
Sposito, A.C.2
-
20
-
-
84924614491
-
Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective
-
PID: 25155010
-
Fisher M. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. Diabetes Obes Metab. 2015;17:335–42.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 335-342
-
-
Fisher, M.1
-
21
-
-
84899896600
-
Genetic association analysis of 30 genes related to obesity in a European American population
-
Li P, Tiwari HK, Lin WY, Allison DB, Chung WK, Leibel RL, et al. Genetic association analysis of 30 genes related to obesity in a European American population. Int J Obes. 2014;38(5):724–9.
-
(2014)
Int J Obes
, vol.38
, Issue.5
, pp. 724-729
-
-
Li, P.1
Tiwari, H.K.2
Lin, W.Y.3
Allison, D.B.4
Chung, W.K.5
Leibel, R.L.6
-
22
-
-
84924347310
-
Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes
-
PID: 25785276
-
Lin CH, Lee YS, Huang YY, Hsieh SH, Chen ZS, Tsai CN. Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes. J Diabetes Res. 2015;2015:176949.
-
(2015)
J Diabetes Res
, vol.2015
, pp. 176949
-
-
Lin, C.H.1
Lee, Y.S.2
Huang, Y.Y.3
Hsieh, S.H.4
Chen, Z.S.5
Tsai, C.N.6
-
23
-
-
80054110585
-
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
-
PID: 21786155
-
Nagashima M, Watanabe T, Terasaki M. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011;54:2649–59.
-
(2011)
Diabetologia
, vol.54
, pp. 2649-2659
-
-
Nagashima, M.1
Watanabe, T.2
Terasaki, M.3
-
24
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
PID: 15616022
-
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146–51.
-
(2005)
Diabetes
, vol.54
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
Brand, C.L.4
Yellon, D.M.5
-
25
-
-
84908042187
-
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
-
PID: 25117407
-
DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, et al. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab. 2014;307(8):E630–43.
-
(2014)
Am J Physiol Endocrinol Metab
, vol.307
, Issue.8
, pp. E630-E643
-
-
DeNicola, M.1
Du, J.2
Wang, Z.3
Yano, N.4
Zhang, L.5
Wang, Y.6
-
26
-
-
84908101883
-
AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes
-
PID: 25128166
-
Balteau M, Van Steenbergen A, Timmermans AD, Dessy C, Behets-wydemans G, Tajeddine N, et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am J Physiol Heart Circ Physiol. 2014;307(8):H1120–33.
-
(2014)
Am J Physiol Heart Circ Physiol
, vol.307
, Issue.8
, pp. H1120-H1133
-
-
Balteau, M.1
Van Steenbergen, A.2
Timmermans, A.D.3
Dessy, C.4
Behets-wydemans, G.5
Tajeddine, N.6
-
27
-
-
84922771067
-
Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease
-
PID: 25677437
-
Akiyama E, Sugiyama S, Matsubara J, Kurokawa H, Konishi M, Nozaki T, et al. Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease. J Am Coll Cardiol. 2015;65(7):754–5.
-
(2015)
J Am Coll Cardiol
, vol.65
, Issue.7
, pp. 754-755
-
-
Akiyama, E.1
Sugiyama, S.2
Matsubara, J.3
Kurokawa, H.4
Konishi, M.5
Nozaki, T.6
-
28
-
-
84908252688
-
Glucagon-like peptide-1 levels on admission for acute myocardial infarction with or without acute hyperglycemia
-
PID: 25125017
-
Konishi M, Akiyama E, Matsuzawa Y, Suzuki H, Maejima N, Umemura S, et al. Glucagon-like peptide-1 levels on admission for acute myocardial infarction with or without acute hyperglycemia. Int J Cardiol. 2014;176(3):1214–6.
-
(2014)
Int J Cardiol
, vol.176
, Issue.3
, pp. 1214-1216
-
-
Konishi, M.1
Akiyama, E.2
Matsuzawa, Y.3
Suzuki, H.4
Maejima, N.5
Umemura, S.6
-
29
-
-
58949102483
-
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure–prone rat
-
PID: 19727407
-
Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP, et al. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure–prone rat. Circ Heart Fail. 2008;1:153–60.
-
(2008)
Circ Heart Fail
, vol.1
, pp. 153-160
-
-
Poornima, I.1
Brown, S.B.2
Bhashyam, S.3
Parikh, P.4
Bolukoglu, H.5
Shannon, R.P.6
-
30
-
-
4344605042
-
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
-
PID: 15313949
-
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955–61.
-
(2004)
Circulation
, vol.110
, pp. 955-961
-
-
Nikolaidis, L.A.1
Elahi, D.2
Hentosz, T.3
Doverspike, A.4
Huerbin, R.5
Zourelias, L.6
-
31
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
PID: 14981009
-
Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962–5.
-
(2004)
Circulation
, vol.109
, Issue.8
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
Miske, G.4
Shah, A.5
Elahi, D.6
-
32
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
PID: 17174230
-
Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–9.
-
(2006)
J Card Fail
, vol.12
, Issue.9
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
Elahi, D.4
Shannon, R.P.5
-
33
-
-
34547930879
-
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
-
PID: 17719327
-
Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100(5):824–9.
-
(2007)
Am J Cardiol
, vol.100
, Issue.5
, pp. 824-829
-
-
Sokos, G.G.1
Bolukoglu, H.2
German, J.3
Hentosz, T.4
Magovern, G.J.5
Maher, T.D.6
-
34
-
-
84925355917
-
GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats
-
PID: 25818251
-
Inoue T, Inoguchi T, Sonoda N, Hendarto H. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Atherosclerosis. 2015;240(1):250–9.
-
(2015)
Atherosclerosis
, vol.240
, Issue.1
, pp. 250-259
-
-
Inoue, T.1
Inoguchi, T.2
Sonoda, N.3
Hendarto, H.4
-
35
-
-
84935009269
-
Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix
-
PID: 25725809
-
Robinson E, Cassidy RS, Tate M, Zhao Y, Lockhart S, Calderwood D, et al. Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol. 2015;110:20.
-
(2015)
Basic Res Cardiol
, vol.110
, pp. 20
-
-
Robinson, E.1
Cassidy, R.S.2
Tate, M.3
Zhao, Y.4
Lockhart, S.5
Calderwood, D.6
-
36
-
-
58949084130
-
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
-
PID: 19195607
-
Timmers L, Henriques JPS, De Kleijn DPV, Devries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53(6):501–10.
-
(2009)
J Am Coll Cardiol
, vol.53
, Issue.6
, pp. 501-510
-
-
Timmers, L.1
Henriques, J.P.S.2
De Kleijn, D.P.V.3
Devries, J.H.4
Kemperman, H.5
Steendijk, P.6
-
37
-
-
84891591832
-
Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells
-
PID: 24401231
-
Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, et al. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014;232(1):156–64.
-
(2014)
Atherosclerosis
, vol.232
, Issue.1
, pp. 156-164
-
-
Batchuluun, B.1
Inoguchi, T.2
Sonoda, N.3
Sasaki, S.4
Inoue, T.5
Fujimura, Y.6
-
38
-
-
67650057935
-
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
-
PID: 19136619
-
Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201:59–66.
-
(2009)
J Endocrinol
, vol.201
, pp. 59-66
-
-
Liu, H.1
Dear, A.E.2
Knudsen, L.B.3
Simpson, R.W.4
-
39
-
-
84949110416
-
Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans
-
Koska J, Sands M, Burciu C, Souza KMD, Raravikar K, Liu J, et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes. 2015;64:2624–35.
-
(2015)
Diabetes
, vol.64
, pp. 2624-2635
-
-
Koska, J.1
Sands, M.2
Burciu, C.3
Souza, K.M.D.4
Raravikar, K.5
Liu, J.6
-
40
-
-
84929454304
-
The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs
-
PID: 25897902
-
Zhan J, Wang Y, Wang Y, Tang Z, Tan P, Huang W, et al. The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs. Int J Cardiol. 2015;189:188–93.
-
(2015)
Int J Cardiol
, vol.189
, pp. 188-193
-
-
Zhan, J.1
Wang, Y.2
Wang, Y.3
Tang, Z.4
Tan, P.5
Huang, W.6
-
41
-
-
84859003663
-
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
-
PID: 22236411
-
Vilsboll T, Christense M, Junker AE, Knop FK, Gluud L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
-
(2012)
BMJ
, vol.344
, pp. d7771
-
-
Vilsboll, T.1
Christense, M.2
Junker, A.E.3
Knop, F.K.4
Gluud, L.5
-
42
-
-
84894527870
-
Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study
-
PID: 24326527
-
Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, et al. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Diabetologia. 2014;57(3):455–62.
-
(2014)
Diabetologia
, vol.57
, Issue.3
, pp. 455-462
-
-
Kim, S.H.1
Liu, A.2
Ariel, D.3
Abbasi, F.4
Lamendola, C.5
Grove, K.6
-
43
-
-
84940751369
-
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
-
PID: 26338040
-
Simó R, Guerci B, Schernthaner G, Gallwitz B, Guzmàn JR, Dotta F, et al. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol. 2015;14:116.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 116
-
-
Simó, R.1
Guerci, B.2
Schernthaner, G.3
Gallwitz, B.4
Guzmàn, J.R.5
Dotta, F.6
-
44
-
-
33748442464
-
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
-
PID: 16776751
-
Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436–47.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 436-447
-
-
Blonde, L.1
Klein, E.J.2
Han, J.3
Zhang, B.4
Mac, S.M.5
Poon, T.H.6
-
45
-
-
77958184434
-
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition
-
PID: 20424219
-
Bunck MC, Diamant M, Eliasson B, Corner A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33(8):1734–7.
-
(2010)
Diabetes Care
, vol.33
, Issue.8
, pp. 1734-1737
-
-
Bunck, M.C.1
Diamant, M.2
Eliasson, B.3
Corner, A.4
Shaginian, R.M.5
Heine, R.J.6
-
46
-
-
84920007637
-
Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes
-
PID: 25280957
-
Ariel D, Kim SH, Abbasi F, Lamendola CA, Liu A, Reaven GM. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutr Metab Cardiovasc Dis. 2014;24(12):1317–22.
-
(2014)
Nutr Metab Cardiovasc Dis
, vol.24
, Issue.12
, pp. 1317-1322
-
-
Ariel, D.1
Kim, S.H.2
Abbasi, F.3
Lamendola, C.A.4
Liu, A.5
Reaven, G.M.6
-
47
-
-
84891883623
-
Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes
-
PID: 23835684
-
Kim SH, Abbasi F, Lamendola C, Liu A, Reaven G. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36:3276–82.
-
(2013)
Diabetes Care
, vol.36
, pp. 3276-3282
-
-
Kim, S.H.1
Abbasi, F.2
Lamendola, C.3
Liu, A.4
Reaven, G.5
-
48
-
-
84936166069
-
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
-
PID: 26132939, Large-scale RCT demonstrating that liraglutide is associated with weight loss, along with favorable effects on other CVD risk factors including lipid profiles
-
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. Large-scale RCT demonstrating that liraglutide is associated with weight loss, along with favorable effects on other CVD risk factors including lipid profiles.
-
(2015)
N Engl J Med
, vol.373
, Issue.1
, pp. 11-22
-
-
Pi-Sunyer, X.1
Astrup, A.2
Fujioka, K.3
Greenway, F.4
Halpern, A.5
Krempf, M.6
-
49
-
-
84940665526
-
Efficacy of liraglutide for weight loss among patients with type 2 diabetes
-
PID: 26284720, Large-scale RCT demonstrating that liraglutide is associated with weight loss, along with favorable effects on other CVD risk factors including lipid profiles
-
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA. 2015;314(7):687. Large-scale RCT demonstrating that liraglutide is associated with weight loss, along with favorable effects on other CVD risk factors including lipid profiles.
-
(2015)
JAMA
, vol.314
, Issue.7
, pp. 687
-
-
Davies, M.J.1
Bergenstal, R.2
Bode, B.3
Kushner, R.F.4
Lewin, A.5
Skjøth, T.V.6
-
50
-
-
84920694437
-
Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers
-
PID: 25458329
-
Gurkan E, Tarkun I, Sahin T, Cetinarslan B. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers. Diabetes Res Clin Pract. 2014;106(3):567–75.
-
(2014)
Diabetes Res Clin Pract
, vol.106
, Issue.3
, pp. 567-575
-
-
Gurkan, E.1
Tarkun, I.2
Sahin, T.3
Cetinarslan, B.4
-
51
-
-
84920053430
-
Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes
-
PID: 25414155
-
Lovshin JA, Barnie A, Dealmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38:132–9.
-
(2015)
Diabetes Care
, vol.38
, pp. 132-139
-
-
Lovshin, J.A.1
Barnie, A.2
Dealmeida, A.3
Logan, A.4
Zinman, B.5
Drucker, D.J.6
-
52
-
-
84945492252
-
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
-
Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, De Loredo L, Boopalan A, et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2015.
-
(2015)
Diabetes Obes Metab
-
-
Ahmann, A.1
Rodbard, H.W.2
Rosenstock, J.3
Lahtela, J.T.4
De Loredo, L.5
Boopalan, A.6
-
53
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
-
PID: 20609969
-
Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–43.
-
(2010)
Lancet
, vol.375
, Issue.9733
, pp. 2234-2243
-
-
Diamant, M.1
Van Gaal, L.2
Stranks, S.3
Northrup, J.4
Cao, D.5
Taylor, K.6
-
54
-
-
84943197778
-
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis
-
Sun F, Wu S, Guo S, Yu K, Yang Z. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015.
-
(2015)
Diabetes Res Clin Pract
-
-
Sun, F.1
Wu, S.2
Guo, S.3
Yu, K.4
Yang, Z.5
-
55
-
-
80052518181
-
Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis
-
PID: 21624032
-
Peskin BR, Shcheprov AV, Boye KS, Bruce S, Maggs DG, Gaebler JA. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes Obes Metab. 2011;13:921–7.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 921-927
-
-
Peskin, B.R.1
Shcheprov, A.V.2
Boye, K.S.3
Bruce, S.4
Maggs, D.G.5
Gaebler, J.A.6
-
56
-
-
84863560602
-
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
-
PID: 21920963
-
Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491–9.
-
(2012)
Eur Heart J
, vol.33
, pp. 1491-1499
-
-
Lønborg, J.1
Vejlstrup, N.2
Kelbæk, H.3
Bøtker, H.E.4
Kim, W.Y.5
Mathiasen, A.B.6
-
57
-
-
84883295202
-
Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention results of exenatide myocardial protection in revascularization study
-
PID: 23868944
-
Woo JS, Kim W, Ha SJ, Kim JB, Kim S, Kim W, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013;33:2252–60.
-
(2013)
Arterioscler Thromb Vasc Biol
, vol.33
, pp. 2252-2260
-
-
Woo, J.S.1
Kim, W.2
Ha, S.J.3
Kim, J.B.4
Kim, S.5
Kim, W.6
-
58
-
-
70350619609
-
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
-
PID: 19853906
-
Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–16.
-
(2009)
Lancet
, vol.374
, Issue.9701
, pp. 1606-1616
-
-
Astrup, A.1
Rössner, S.2
Van Gaal, L.3
Rissanen, A.4
Niskanen, L.5
Al Hakim, M.6
-
59
-
-
84928314796
-
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study
-
PID: 25896352
-
Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol. 2015;14:41.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 41
-
-
Faber, R.1
Zander, M.2
Pena, A.3
Michelsen, M.M.4
Mygind, N.D.5
Prescott, E.6
-
60
-
-
84890572455
-
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk : a meta-analysis of randomized clinical trials
-
PID: 23829656, Meta-analysis examining the effects of GLP-1 agonists on cardiovascular outcomes, showing unclear benefit of these agents on population-level outcomes
-
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38–47. Meta-analysis examining the effects of GLP-1 agonists on cardiovascular outcomes, showing unclear benefit of these agents on population-level outcomes.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 38-47
-
-
Monami, M.1
Dicembrini, I.2
Nardini, C.3
Fiordelli, I.4
Mannucci, E.5
-
61
-
-
84960088756
-
Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: a large database study from the Cleveland Clinic
-
Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: a large database study from the Cleveland Clinic. J Diabetes. 2015.
-
(2015)
J Diabetes
-
-
Kannan, S.1
Pantalone, K.M.2
Matsuda, S.3
Wells, B.J.4
Karafa, M.5
Zimmerman, R.S.6
-
62
-
-
84929289581
-
Rationale, design, and baseline characteristics in evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
-
PID: 25965710, One of several ongoing large-scale trials directly examining the effect of GLP-1 agonists, lixisenatide in this case, on cardiovascular outcomes
-
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169(5):631–8.e7. One of several ongoing large-scale trials directly examining the effect of GLP-1 agonists, lixisenatide in this case, on cardiovascular outcomes.
-
(2015)
Am Heart J
, vol.169
, Issue.5
, pp. 631-807
-
-
Bentley-Lewis, R.1
Aguilar, D.2
Riddle, M.C.3
Claggett, B.4
Diaz, R.5
Dickstein, K.6
-
63
-
-
84958800611
-
-
Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA). Available from:. Accessed 30 Oct 2015
-
Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA). Available from: https://clinicaltrials.gov/ct2/show/NCT01147250. Accessed 30 Oct 2015.
-
-
-
-
64
-
-
84948740668
-
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
-
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.
-
(2015)
N Engl J Med
, vol.373
, pp. 2247-2257
-
-
Pfeffer, M.A.1
Claggett, B.2
Diaz, R.3
Dickstein, K.4
Gerstein, H.C.5
-
65
-
-
84916607012
-
Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs—a nested case–control study
-
PID: 25465309
-
Gejl M, Starup-Linde J, Scheel-thomsen J, Gregersen S, Vestergaard P. Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs—a nested case–control study. Int J Cardiol. 2015;178:292–6.
-
(2015)
Int J Cardiol
, vol.178
, pp. 292-296
-
-
Gejl, M.1
Starup-Linde, J.2
Scheel-thomsen, J.3
Gregersen, S.4
Vestergaard, P.5
-
66
-
-
84926138389
-
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes : an individual participant data meta-analysis of randomized controlled trials
-
PID: 25656522
-
Seshasai SRK, Bennett RL, Petrie JR, Bengus M, Ekman S, Dixon M, et al. Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17:505–10.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 505-510
-
-
Seshasai, S.R.K.1
Bennett, R.L.2
Petrie, J.R.3
Bengus, M.4
Ekman, S.5
Dixon, M.6
-
67
-
-
84886946727
-
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial
-
PID: 24176437
-
Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823–30.e5.
-
(2013)
Am Heart J
, vol.166
, Issue.5
, pp. 823-825
-
-
Marso, S.P.1
Poulter, N.R.2
Nissen, S.E.3
Nauck, M.A.4
Zinman, B.5
Daniels, G.H.6
-
68
-
-
84958800612
-
-
Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results - a long term evaluation (LEADER®). Available from:. Accessed 30 Oct 2015
-
Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results - a long term evaluation (LEADER®). Available from: https://clinicaltrials.gov/ct2/show/NCT01179048. Accessed 30 Oct 2015.
-
-
-
-
69
-
-
84958800613
-
-
Researching cardiovascular events with a weekly incretin in diabetes (REWIND). Available from:. Accessed 30 Oct 2015
-
Researching cardiovascular events with a weekly incretin in diabetes (REWIND). Available from: https://clinicaltrials.gov/ct2/show/NCT01394952. Accessed 30 Oct 2015.
-
-
-
-
70
-
-
84958800614
-
-
TM 6). Available from:. Accessed 30 Oct 2015
-
TM 6). Available from: https://clinicaltrials.gov/ct2/show/NCT01720446. Accessed 30 Oct 2015.
-
-
-
-
71
-
-
84958800615
-
-
Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Available from:. Accessed 30 Oct 2015
-
Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT01144338. Accessed 30 Oct 2015.
-
-
-
|